About Tesamorelin Compound

What this project is

Tesamorelin Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "compound" in the name signals the register we read in: tesamorelin as a chemical entity with a defined structure, a defined mechanism, and a defined evidence base — an instrument-grade reading of the literature, not a storefront and not a consultation. It is an editorial position relative to the published record, not a claim about services this site offers. We hold no inventory, take no orders, and quote no prices.

How we read the evidence

Tesamorelin is the rare research peptide whose record is genuinely strong and genuinely bounded at the same time. Two pivotal Phase 3 RCTs, a JAMA hepatic-fat trial, and a 2026 five-RCT meta-analysis establish real effects in HIV-associated lipodystrophy — the single indication for which it was FDA-approved in 2010. Yet every popular use beyond that population is off-label and investigational, the benefit reverses on discontinuation, and the IGF-1 growth-factor caveat leaves long-term oncologic safety only partly characterized.

So we grade. Every finding on this site carries a confidence label — ESTABLISHED for what the pivotal trials showed in their studied population, INVESTIGATIONAL for the off-label extrapolations, GAP for the honest unknowns, CAUTION for the labeled contraindications. The aim is that you can see the strength of the evidence behind a claim at the same moment you read the claim, rather than trusting a confident sentence on its own. Every quantitative figure is attributed to a study in the references list.

What we do not do

We do not recommend doses for people, name any commercial brand, or imply that tesamorelin is approved for any use beyond HIV-associated lipodystrophy. We describe what was administered to whom, at what dose, by what route, with what measured outcome — and we say plainly where the data stop. Research-grade tesamorelin discussed here is supplied for laboratory use and is not the approved finished drug product; nothing on this site is an instruction to self-administer it.